17. A kit for subcutaneous injection of a highly concentrated, stable anti-HER2 antibody formulation comprising:

A) A vial containing:

a. 120 +/- 18 mg/ml anti-HER2 antibody ~~selected from the group of Trastuzumab, Pertuzumab and T-DM1 or a combination of such antibodies~~;

b. 1 to 50 mM of a histidine buffer providing a pH of 5.5 ± 0.4;

c. 15 to 250 mM of α, α-trehalose dihydrate or sucrose and 5 to 25 mM of methionine~~1 to 500 mM of a stabilizer or a mixture of two or more stabilizers~~;

d. 0.01 to 0.08 % of a nonionic surfactant, wherein said anti-HER2 antibody is Trastuzumab; and

B) A vial containing 150 to 16'000 U/ml, 2000 U/ml or 12'000 U/ml of a hyaluronidase enzyme.

18. The kit according to claim 17 further comprising an injection device for subcutaneous administration of the formulation to a patient.

19. The kit according to claim 17 or 18, wherein the histidine buffer is 20 mM histidine/HCl.

~~20. The kit according to any one of claims 17 to 19, wherein the stabilizer is α,α-trehalose dihydrate or sucrose.~~

~~21. The kit according to any one of claims 17 to 19, wherein the stabilizer is 15 to 250 mM or 210 mM α,α-trehalose dihydrate or sucrose.~~

~~22. The kit according to any one of claims 17 to 21, wherein methionine is used as a second stabilizer.~~

~~23. The kit according to claim 22, wherein methionine is used as a second stabilizer in a concentration of 5 to 25 mM.~~

~~24.~~20. The kit according to any one of claims 17 to ~~23~~19, wherein the nonionic surfactant is a polysorbate selected from the group consisting of polysorbate 20, polysorbate 80, and polyethylene-polypropylene copolymer.

~~25.~~21. The kit according to claim ~~24~~20, wherein the concentration of the non-ionic surfactant is 0.02 % (w/v), 0.04 % (w/v) or 0.06 % (w/v).

***